Total number of subjects and total per cent of subjects on atorvastatin and other statins respectively at lipid close-out visit and final visit. All LLA subjects by atorvastatin and placebo subgroups
| . | Atorvastatin, n = 4978 . | Placebo, n = 4916 . | ||
|---|---|---|---|---|
| . | Atorvastatin, n (%) . | Any statins, n (%) . | Atorvastatin, n (%) . | Any statins, n (%) . |
| Lipid close-out visit | 4113 (82.6%) | 4167 (83.7%) | 415 (8.4) | 635 (12.9%) |
| Final visit | 3122 (62.7%) | 3322 (66.7%) | 2752 (56.0%) | 3089 (62.8%) |
| . | Atorvastatin, n = 4978 . | Placebo, n = 4916 . | ||
|---|---|---|---|---|
| . | Atorvastatin, n (%) . | Any statins, n (%) . | Atorvastatin, n (%) . | Any statins, n (%) . |
| Lipid close-out visit | 4113 (82.6%) | 4167 (83.7%) | 415 (8.4) | 635 (12.9%) |
| Final visit | 3122 (62.7%) | 3322 (66.7%) | 2752 (56.0%) | 3089 (62.8%) |
Total number of subjects and total per cent of subjects on atorvastatin and other statins respectively at lipid close-out visit and final visit. All LLA subjects by atorvastatin and placebo subgroups
| . | Atorvastatin, n = 4978 . | Placebo, n = 4916 . | ||
|---|---|---|---|---|
| . | Atorvastatin, n (%) . | Any statins, n (%) . | Atorvastatin, n (%) . | Any statins, n (%) . |
| Lipid close-out visit | 4113 (82.6%) | 4167 (83.7%) | 415 (8.4) | 635 (12.9%) |
| Final visit | 3122 (62.7%) | 3322 (66.7%) | 2752 (56.0%) | 3089 (62.8%) |
| . | Atorvastatin, n = 4978 . | Placebo, n = 4916 . | ||
|---|---|---|---|---|
| . | Atorvastatin, n (%) . | Any statins, n (%) . | Atorvastatin, n (%) . | Any statins, n (%) . |
| Lipid close-out visit | 4113 (82.6%) | 4167 (83.7%) | 415 (8.4) | 635 (12.9%) |
| Final visit | 3122 (62.7%) | 3322 (66.7%) | 2752 (56.0%) | 3089 (62.8%) |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
